A prediction model to calculate probability of Alzheimer's disease using cerebrospinal fluid biomarkers

Alzheimer's and Dementia

Volumn 9, Issue 3, 2013, Pages 262-268

  Spies, Petra E ^a,b   Claassen, Jurgen A H R ^a,b   Peer, Petronella G M ^a   Blankenstein, Marinus A ^c   Teunissen, Charlotte E ^c   Scheltens, Philip ^d   Van Der Flier, Wiesje M ^c,d   Olde Rikkert, Marcel G M ^a,b   Verbeek, Marcel M ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CSF biomarkers; Dementia; Differential diagnosis; Prediction model; Validation

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; DEMENTIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; PROTEIN PHOSPHORYLATION; RECEIVER OPERATING CHARACTERISTIC; SEX;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MEMORY DISORDERS; MIDDLE AGED; MODELS, STATISTICAL; PREDICTIVE VALUE OF TESTS; PROBABILITY; TAU PROTEINS;

EID: 84876939258     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2012.01.010     Document Type: Article

References (32)

1. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stadlan Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 1984 939 944
2. B. Dubois, H.H. Feldman, C. Jacova, S.T. DeKosky, P. Barberger-Gateau, and J. Cummings Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria Lancet Neurol 6 2007 734 746
3. G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack Jr., and C.H. Kawas The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 263 269
4. K. Blennow Cerebrospinal fluid protein biomarkers for Alzheimer's disease NeuroRx 1 2004 213 225
5. D. de Jong, B.P. Kremer, M.G. Olde Rikkert, and M.M. Verbeek Current state and future directions of neurochemical biomarkers for Alzheimer's disease Clin Chem Lab Med 45 2007 1421 1434
6. E. Vanmechelen, H. Vanderstichele, F. Hulstaert, N. Andreasen, L. Minthon, B. Winblad, P. Davidsson, and K. Blennow Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders Mech Ageing Dev 122 2001 2005 2011
7. M.M. Verbeek, D. de Jong, and H.P. Kremer Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases Ann Clin Biochem 40 2003 25 40
8. P.E. Spies, D. Slats, J.M. Sjogren, B.P. Kremer, F.R. Verhey, M.G. Rikkert, and M.M. Verbeek The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia Curr Alzheimer Res 7 2010 470 476
9. C. Mulder, N.A. Verwey, W.M. van der Flier, FH. Bouwman, A. Kok, E.J. van Elk, P. Scheltens, and M.A. Blankenstein Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease Clin Chem 56 2010 248 253
10. P.E. Spies, D. Slats, I. Ramakers, F.R. Verhey, and M.G. Olde Rikkert Experiences with cerebrospinal fluid analysis in Dutch memory clinics Eur J Neurol 18 2011 1014 1016
11. G. De Meyer, F. Shapiro, H. Vanderstichele, E. Vanmechelen, S. Engelborghs, and P.P. De Deyn Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people Arch Neurol 67 2010 949 956
12. F. Hulstaert, K. Blennow, A. Ivanoiu, H.C. Schoonderwaldt, M. Riemenschneider, and P.P. De Deyn Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF Neurology 52 1999 1555 1562
13. J.C. Van Houwelingen, and S. Le Cessie Predictive value of statistical models Stat Med 9 1990 1303 1325
14. K.J. Janssen, Y. Vergouwe, C.J. Kalkman, D.E. Grobbee, and K.G. Moons A simple method to adjust clinical prediction models to local circumstances Can J Anaesth 56 2009 194 201
15. M. Smits, D.W. Dippel, E.W. Steyerberg, G.G. de Haan, HM. Dekker, and P.E. Vos Predicting intracranial traumatic findings on computed tomography in patients with minor head injury: the CHIP prediction rule Ann Intern Med 146 2007 397 405
16. E.W. Steyerberg Clinical prediction models 1st ed. 2009 Springer Berlin, Germany
17. E.W. Steyerberg, G.J. Borsboom, H.C. van Houwelingen, M.J. Eijkemans, and J.D. Habbema Validation and updating of predictive logistic regression models: a study on sample size and shrinkage Stat Med 23 2004 2567 2586
18. K.J. Janssen, K.G. Moons, C.J. Kalkman, D.E. Grobbee, and Y. Vergouwe Updating methods improved the performance of a clinical prediction model in new patients J Clin Epidemiol 61 2008 76 86
19. Alzheimer's Association Cerebrospinal Fluid Quality Control Program. Available at: http://www.neurophys.gu.se/sektioner/psykiatri-och-neurokemi/ neurokem/thealzassqcprogram. Accessed September 1, 2011.
20. N. Mattsson, U. Andreasson, S. Persson, H. Arai, S.D. Batish, and S. Bernardini The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers Alzheimers Dement 7 2011 386 395
21. J. Vina, and A. Lloret Why women have more Alzheimer's disease than men: gender and mitochondrial toxicity of amyloid-beta peptide J Alzheimers Dis 20 Suppl 2 2010 S527 S533
22. B.L. Plassman, K.M. Langa, G.G. Fisher, S.G. Heeringa, D.R. Weir, and M.B. Ofstedal Prevalence of dementia in the United States: the aging, demographics, and memory study Neuroepidemiology 29 2007 125 132
23. D. de Jong, R.W. Jansen, B.P. Kremer, and M.M. Verbeek Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia J Gerontol A Biol Sci Med Sci 61 2006 755 758
24. E.B. Mukaetova-Ladinska, R. Monteith, and E.K. Perry Cerebrospinal fluid biomarkers for dementia with lewy bodies Int J Alzheimers Dis 2010 2010 536538
25. N.S. Schoonenboom, Y.A. Pijnenburg, C. Mulder, S.M. Rosso, E.J. van Elk, G.J. Van Kamp, J.C. Van Swieten, and P. Scheltens Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease Neurology 62 2004 1580 1584
26. N.A. Verwey, W.M. van der Flier, K. Blennow, C. Clark, S. Sokolow, and P.P. De Deyn A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease Ann Clin Biochem 46 2009 235 240
27. N. Mattsson, H. Zetterberg, O. Hansson, N. Andreasen, L. Parnetti, and M. Jonsson CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment JAMA 302 2009 385 393
28. B. Schmand, H.M. Huizenga, and W.A. van Gool Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease Psychol Med 40 2010 135 145
29. I. van Rossum, S. Vos, R. Handels, and P.J. Visser Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design J Alzheimers Dis 20 2010 881 891
30. P.J. Visser, F. Verhey, D.L. Knol, P. Scheltens, L.O. Wahlund, and Y. Freund-Levi Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study Lancet Neurol 8 2009 619 627
31. P. Scheltens, and K. Rockwood How golden is the gold standard of neuropathology in dementia? Alzheimers Dement 7 2011 486 489
32. C.C. Rowe, K.A. Ellis, M. Rimajova, P. Bourgeat, K.E. Pike, and G. Jones Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging Neurobiol Aging 31 2010 1275 1283